About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, February 28th, 2018

The QualityStocks
Daily Stock List


StartMonday Technology Corp. (STMDF)

Dividend Investor, OTC Markets, Stockhouse, MarketWatch, Barchart, GuruFocus, Science of Stocks, Investorx.ca, and Penny Stock Hub reported on StartMonday Technology Corp. (STMDF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

StartMonday Technology Corp. engages in candidate selection solutions for employers in the retail and hospitality sectors. The Company helps employers choose better candidates, quicker, with the power of 15-second video introductions. A smart recruitment technology enterprise, StartMonday Technology has its corporate headquarters in Vancouver, British Columbia. The Company’s shares trade on the OTC Markets Group’s OTCQB.

StartMonday Technology was founded by professionals from the recruiting and tech fields - Ray Gibson from recruiting and HR, and Andrew Evans from the founding team at Careerbuilder.com.

StartMonday Technology’s commitment is to building strong tools for the Mobile Generation. Moreover, the Company is further developing its technology with an open blockchain solution for verifiable career histories named CareerChain.
StartMonday's video-led mobile and web applications deliver a better impression of customer skills and personality, ultimately assisting employers in deciding which candidates they should talk to first. This makes the process much more efficient.

StartMonday's core products center around 15-second videos filmed by candidates on their own mobile phones and web browsers. This puts job applications decisively in the social media and mobile native arena.

This enables job seekers to present themselves in their own way. In addition to lessening cost and time-to-hire, the Company brings massive employer branding opportunities to its clients.

Last week, StartMonday Technology announced that it has partnered with Talent Tech Labs (TTL)- Manhattan-based, as part of their late-stage accelerator program targeted at advancing select, mature startups ready for targeted penetration into the North American market. Talent Tech Labs is a sector leader in the knowledge and analysis of up-and-coming trends and technologies applied to improving the state of the art of recruitment.

StartMonday Co-Founder and Chief Executive Officer, Mr. Ray Gibson said, “We are extremely pleased to have been selected for the TTL accelerator program. This is a limited and very influential opportunity that has previously proven its worth at propelling entry into the U.S. marketplace… We believe this program will ideally position us to really show what StartMonday and CareerChain can do to accelerate success within the HR industry arm of Corporate America.”

StartMonday Technology Corp. (STMDF), closed Wednesday's trading session at $0.31, up 0.16%, on 465,817 volume with 405 trades. The average volume for the last 60 days is 17,970 and the stock's 52-week low/high is $0.219/$0.5005.

Abtech Holdings, Inc. (ABHD)

Greenbackers, Stealth Stocks, Wyatt Investment Research, Investor Ideas, Stock Mister, OTC Journal, The Stock Psycho, Wall Street Resources, FeedBlitz, Topgun stockpicks, Hidden Values Alert, CoolPennyStocks, and AllPennyStocks reported earlier on Abtech Holdings, Inc. (ABHD), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Abtech Holdings, Inc. is a full-service environmental technologies and engineering company. It provides creative solutions to communities, industry, as well as governments addressing issues of water pollution and contamination. Abtech provides solutions for Stormwater Management, Oil & Gas Water Treatment, and Industrial Water Treatment. OTCQB-listed, Abtech Holdings is based in Scottsdale, Arizona. AbTech Industries, Inc. is a subsidiary of Abtech Holdings.

Abtech began marketing of produced water and industrial wastewater treatment, and established its engineering subsidiary AEWS Engineering in 2012. AEWS is an independent civil and environmental engineering firm partnered with foremost research and engineering universities.

The foundation of Abtech’s products is on polymer technologies, which can remove hydrocarbons, sediment, and other foreign elements in stormwater runoff, flowing water, and industrial process and wastewater. Abtech’s products include advanced filtration media technologies and different water treatment systems.

The Company’s offerings include the antimicrobial technology- Smart Sponge® Plus. This technology is effective in reducing coliform bacteria found in stormwater, industrial wastewater, and municipal wastewater. Smart Sponge® Plus is registered with the Environmental Protection Agency (EPA).

Abtech has installed and validated onsite its first mobile water pre-treatment system centered on oil recovery and hydrocarbon removal for the treatment of flowback and produced water for the on-shore Oil & Gas industry. This pre-treatment system integrates its Smart Sponge® technology. The design of it is to operate in advance of other treatment systems, boosting overall efficiency and lessening treatment cost.

Abtech Holdings continued its activity in 2017 with several water treatment field trials. It prepared for the second field test of evaporative technology for produced and frac flowback water with a concentration on emissions. It successfully completed a Smart Sponge® hydrocarbon removal and recycling of spent media demonstration in a produced water application for its Colombian distributor, advancing discussions to economics and design issues. In addition, it achieved low phosphorus results on a sanitary wastewater application in China.

In July 2017, Abtech Holdings announced that it and United Stormwater, Inc. collaborated to bring two best-in-class technologies together, providing an inventive solution for developing stormwater challenges in southern California.

A municipality in Los Angeles County, California retrofitted existing infrastructure using United Stormwater's Wing-Gate™ Screens, auto-retractable curb inlet screen covers, and Abtech's Ultra-Urban® Filters, catch basin inserts, so as to prevent stormwater contamination that flows into Legg Lake, one of Los Angeles County's biggest and most popular recreation areas. United Stormwater is a full service stormwater management company.

Abtech Holdings, Inc. (ABHD), closed Wednesday's trading session at $0.013, up 13.04%, on 40,000 volume with 1 trade. The average volume for the last 60 days is 33,097 and the stock's 52-week low/high is $0.0105/$0.024.

Bluestone Resources, Inc. (BBSRF)

MarketWatch, 4-Traders, OTC Markets, Barchart, Dividend Investor, Investors Hangout, OtcStockWatch.com, and Penny Stock Hub reported on Bluestone Resources, Inc. (BBSRF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

A mineral exploration and development company, Bluestone Resources, Inc. concentrates on advancing its 100 percent owned Cerro Blanco Gold and Mita Geothermal Projects in Guatemala. On February 14, 2018, the Company announced that its common shares began trading on the OTCQB Venture Marketplace. Bluestone Resources trades now on the OTCQB Venture under the symbol "BBSRF". Its common shares continue to trade on the TSX Venture Exchange under the symbol "BSR". Bluestone Resources has its corporate headquarters in Vancouver, British Columbia.

The Cerro Blanco Project economics and updated mineral resource estimate for Cerro Blanco indicates a strong project with an expected nine-year mine life producing 952,000 ounces of gold and 3,141,000 ounces of silver. Initial capital expenditures estimated in the Preliminary Economic Assessment (PEA) to fund construction and commissioning is estimated at US$170.8 million with all in sustaining cash estimated to be US$490 per ounce of gold produced. The Cerro Blanco Project is a classic hot springs-related, low sulphidation gold-silver deposit.

Last month, Bluestone Resources provided an update concerning the permitted Mita Geothermal Project situated adjacent to Bluestone’s Cerro Blanco Gold Project in Guatemala. The Mita Geothermal Project is in southeast Guatemala, roughly 160 kilometers by road from the capital, Guatemala City. The Company’s Board of Directors approved a flow test program to further test select geothermal wells with the aim of upgrading the confidence level of the known geothermal reservoir. The data collected will provide the foundation for the development strategy going forward.

A total of 19 geothermal wells have been drilled at the Mita Geothermal Project. This includes nine slim holes and ten standard diameter wells. US$60 million has been invested into this Project so far.

The Mita geothermal resource was discovered in the late 1990’s during gold exploration in southeastern Guatemala. Bluestone Resources controls the necessary surface rights for the Mita Geothermal Project and the Cerro Blanco Project. The Cerro Blanco Gold Project is not dependent on the Mita Geothermal Project. However, Company Management’s belief is that there are potential synergies between the two, which enhance the economics of the Cerro Blanco Gold Project beyond what was outlined in the PEA.

In addition, in January, Bluestone Resources announced an update on the exploration and in-fill drilling program now taking place at its Cerro Blanco Gold Project. The work is being undertaken in combination with the start of the Feasibility Study (FS) announced on September 18, 2017.

Recent results include numerous high-grade underground channel sample assays, for example 270.5 g/t Au and 637 g/t Ag over 2.5 m, which continue to confirm the bonanza-style veins and vein swarms at Cerro Blanco. Three drill rigs are presently operational on surface. Furthermore, an underground in-fill drill program has now started.

Last week, Bluestone Resources announced the creation of a Technical Advisory Committee (TAC). This is to provide impartial advice and peer review over the Cerro Blanco FS, expected to be completed by the end of this year. This Committee will help identify risks and opportunities working closely with Bluestone Resources’ Management and Consultants on material technical elements of the project.

A.L (Alf) Hills will Chair the Technical Advisory Committee. The composition of the committee will be made up of six members. These are Alf Hills, Allan Moss, Roger Nendick, Donald Scott, Robert Sim and Ward Wilson.

Bluestone Resources, Inc. (BBSRF), closed Wednesday's trading session at $1.1256, down 3.83%, on 600 volume with 2 trades. The average volume for the last 60 days is 3,177 and the stock's 52-week low/high is $0.8593/$1.35.

China YCT International Group, Inc. (CYIG)

PennyStockCrowd, Marquee Penny Stocks, Penny Stock Rumble, PennyStocksV2, SquawkBoxStocks, Penny Pick Finders, TerrificPennyStocks, AwesomeStocks, PennyStocks24, Buzz Stocks, Breaking Bulls, Chatter Box Stocks, MyBestStockAlerts, and Planet Pennies reported earlier on China YCT International Group, Inc. (CYIG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

China YCT International Group, Inc is a developer, manufacturer, as well as distributor of traditional Chinese medicines (TCM). The Company engages in the business of developing, manufacturing, and selling medicine, developing acer truncatum bunge planting bases and manufacturing and selling the seed oil, and distributing healthcare supplement products manufactured by a third party. A diversified company, China YCT International Group is headquartered in Sishui County, Shandong Province, China. The Company lists on the OTC Markets’ OTCQB.

China YCT engages in developing, manufacturing, and selling its own TCM’s made primarily from ginseng extract, manufacturing and distributing acertruncatumbunge seed oils, and distributing the abovementioned health care supplement products in China.

Acer Truncatum is a kind of maple. It has 300 species around the world. The Acer Truncatum oil contains 5.8 percent of nervonic acid. Acer Truncatum is contained in plants, and nervonic acid can undergo extraction from these very economically.

Acer Truncatum is only available in China. After more than four decades research and experiments, the Chinese government approved Acer Truncatum oil as general wood food oil that can be used as a general food oil, such as soybean, corn, olive, and other food oils.

The Company announced in May of 2017 that it signed an agreement to purchase the Acer Truncatum business from Shandong YCT Group Co. Ltd. The expectation is that this new business will boost sales by a billion U.S. dollars for China YCT in the next 5 years.

At the beginning of this month, China YCT International Group announced that Shandong Spring Pharmaceutical Co., Ltd., a 97 percent owned subsidiary of the Company, was ratified and issued a Food Production License for production of edible vegetable oil. This includes acer truncatum bunge seed oil, and related blended edible oil products. The License was granted by the Food and Drug Administration of Sishui County. It is valid for five years.

In addition, this month, China YCT International Group announced its financial results for the three and nine months ended December 31, 2017. Total Revenues rose by 21.4 percent year-over-year to $17.21 million. There was growth in sales across all three product categories - acertruncatumbunge seed oil, health care products, and Huoliyuan capsules.

Overall Gross Margin was 39.4 percent for the three months ended December 31, 2017, versus 41.0 percent for the same period of the previous fiscal year. Net Income attributable to China YCT was $2.78 million, or $0.09 per share, for the three months ended December 31, 2017, versus $2.59 million, or $0.09 per share, for the same period of the previous fiscal year.

China YCT International Group, Inc. (CYIG), closed Wednesday's trading session at $0.60, even for the day, on 1 volume with 1 trades. The average volume for the last 60 days is 4,458 and the stock's 52-week low/high is $0.046/$0.95.

Titan Medical, Inc. (TITXF)

BullRally, PennyStockVille, StockRich, OTC Markets Group, CoolPennyStocks, HotOTC, MadPennyStocks, and Sharemkt Tips reported earlier on Titan Medical, Inc. (TITXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Titan Medical, Inc. centers on the design, development, and commercialization of a robotic surgical system for application in minimally invasive surgery (MIS). Currently under development, the Company’s SPORT Surgical System includes a surgeon-controlled robotic platform that features multi-articulating instruments for performing MIS procedures via a single port. A medical device company, Titan Medical is based in Toronto, Ontario. The Company lists on the OTC Markets Group’s OTCQB.

The SPORT Surgical System is a unique single incision robotic surgical system. It has undergone development based on clinical user needs. It is covered by 14 patents and 37 pending applications.

The SPORT Surgical System provides access to underserved market segments, such as ambulatory surgery centers. Regarding Open Display, the 3D high definition 32-inch display provides a first-rate balance of surgical immersion and situational awareness in the Operating Room (OR).

Titan’s surgical system includes a workstation that provides a surgeon with an advanced ergonomic interface to the robotic platform for controlling the instruments and also provides a 3D high-definition endoscopic view inside a patient's body. The design of the SPORT system is to enable surgeons to perform a comprehensive set of general abdominal, gynecologic, urologic, and colorectal procedures. The design of the system is for improved clinical capabilities, operating room efficiency, and hospital economics.

Titan Medical has completed initial formative human factors studies for its SPORT single port robotic surgical system. Formative human factors studies involve the evaluation of prototypes by expert users that focus on simulated task exercises vital to product safety. Titan Medical is planning to commercialize its single incision surgical system - first in Europe and then in the United States.

Earlier this month, Titan Medical announced the granting of Canadian Patent CA 2973227 and CA 2973235. These patents are related generally to control methods for robotic surgical systems. This includes the provision of select autonomous control and safety functions that enable optimal controllability of robotic instruments during use.

The methods describe alignment control of robotic instruments, including snake-like or multi-articulated instruments as utilized in the SPORT system that are important for facilitating movement within the abdomen. Corresponding patent applications are pending in the United States and Europe. Titan anticipates future issuances in numerous jurisdictions.

Last week, Titan Medical reported the successful first use of its SPORT Surgical System in Europe. These studies in general and urologic surgery at the Institute of Image-Guided Surgery at the Institut Hospitalo-Universitaire de Strasbourg, France are part of the feasibility and validation studies intended to support regulatory submissions.

Mr. David McNally, Titan Medical President and Chief Executive Officer, said, “After our installation of the SPORT system at IHU Strasbourg earlier this month, surgeons have now successfully completed the first preclinical single-port robotic surgeries in Europe using the SPORT system. We are honored that highly-regarded surgeons …directed and performed a variety of abdominal, oncologic and urologic procedures. These first-use studies provide valuable insight into procedures we may focus on during commercialization.”

Titan Medical, Inc. (TITXF), closed Wednesday's trading session at $0.31, up 0.71%, on 200,878 volume with 72 trades. The average volume for the last 60 days is 781,143 and the stock's 52-week low/high is $0.096/$0.535.

Alliance BioEnergy Plus, Inc. (ALLM)

Stocks That Move reported earlier on Alliance BioEnergy Plus, Inc. (ALLM), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Alliance BioEnergy Plus, Inc. focuses on the commercialization and licensing of a patented cellulose conversion technology. It controls this technology through a master license agreement with the University of Central Florida. Alliance BioEnergy Plus’s subsidiaries focus on developing technologies in the renewable energy, bio-fuels, as well as new technologies sectors. OTCQB-listed, Alliance BioEnergy Plus is headquartered in West Palm Beach, Florida.

The Company operates various subsidiaries. AMG Energy Group, LLC owns 50 percent of Carbolosic, LLC (in a joint venture (JV) with Thor Renewable Energy Singapore) and exclusively the territories of North America and Africa. Carbolosic holds the exclusive worldwide license for the patented CTS™ (Cellulose to Sugar) process, developed and owned by the University of Central Florida.

Carbolosic holds the exclusive, worldwide license to four issued patents and 14 filed and pending patents revolving around the core CTS (cellulose to sugar) technology.

The CTS™ process converts cellulose into commercial grade sugars, fine chemicals, and other highly valuable products. Alliance BioEnergy Plus’s intention is to center on the production of these commercial products by way of company-owned and licensed facilities

The Company’s commercial pilot/demonstration and research facility, Ek Laboratories, LLC, came online in early 2015. Under the direction of CTS™ inventor Dr. Richard Blair, the facility is running the CTS process, at a commercial scale, and is providing licensees with real time analytics.

The AMG Energy Group subsidiary was created to be the technology arm of the Company. AMG concentrates on the licensing of Alliance BioEnergy Plus’s Intellectual Property (IP), engineering and construction of CTS plants, and developing technologies in the renewable energy, bio-fuels, and new technology sectors.

The CTS Cellulose Ethanol technology can produce a high quality, clean burning Ethanol from almost any plant material less costly, faster, and without any hazardous inputs. The Company has completed the construction of its commercial scale CTS demonstration plant and research laboratories at its subsidiary Central Florida Institute of Science and Technology, Inc. (CFIST).

Alliance BioEnergy Plus earlier filed an 8K with the SEC (Securities and Exchange Commission) disclosing that its subsidiary, Alliance Bio-Products, Inc., entered into a material definitive agreement to purchase the closed ethanol facility in Indian River County, Florida.

The Company received approval from the United States Department of Agriculture (USDA) Office of Rural Development (USDA Rural Development) to move ahead with the purchase in early July 2017. The approved purchase, at a price of $8M, includes the fully functional plant, 144-plus acres that the plant resides on, and all related equipment and vehicles.

Recently, Alliance BioEnergy Plus announced that wholly-owned subsidiary, Ek Laboratories, received a six-figure payment from Phoenix Biomaterials Thomaston, LLC, upon their completion of due diligence of the CTS process, for successful feedstock evaluation and also preliminary engineering reports, related to building a Greenfield (new plant from the ground up) CTS plant. Phoenix’s intention is to enter into a sublicense agreement with the Company once they finalize the logistics of their initial site based on the reports purchased from Alliance BioEnergy Plus.

Alliance BioEnergy Plus, Inc. (ALLM), closed Wednesday's trading session at $0.042, down 6.67%, on 485,737 volume with 47 trades. The average volume for the last 60 days is 976,222 and the stock's 52-week low/high is $0.02/$0.40.

Grow Solutions Holdings, Inc. (GRSO)

Journal Transcript, Profitable Trader Authority, Stockgoodies, PennyStockScholar, OTCtipReporter, StockRockandRoll, ResearchOTC, Elite Stock Alerts, and PennyStockLocks reported previously on Grow Solutions Holdings, Inc. (GRSO), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Established in 2014, Grow Solutions Holdings, Inc. provides complete support services in the broad area of high-yield indoor agriculture. The Company specializes in, but is not limited to, the legal and regulated growing and processing of cannabis. Its corporate mission is to be recognized as the world’s top authority in the indoor high-yield agriculture industry.

In essence, Grow Solutions concentrates on the development/distribution of high-demand products and services for cultivation, processing, and consumption of cannabis. The Company is headquartered in Denver, Colorado. Grow Solutions Holdings’ shares trade on the OTC Markets Group’s OTCQB.

Grow Solutions’ diversified platform of operations and services for the industry consists of its Growth Technologies division (products needed to grow cannabis in and outside), its Consumer Technologies division (products to process, store and consume cannabis), and its Digital Properties division (online properties, including a state-of-the-art employment platform).

In May of 2015, Grow Solutions Holdings acquired Boulder, Colorado-based One Love Garden Supply. One Love is a full-service garden and grow store, which Grow Solutions expanded to over 7,000 square feet of space.

Grow Solutions also acquired HyGrow in September of 2015. This acquisition is to expand its gardening supplies and agricultural products business. The acquisition enabled it to expand into Denver and Pueblo, Colorado.

Grow Solutions has developed and launched FutureTech Products of Pompano, Florida. FutureTech develops products for the consumer market to sell in smoke shops, head shops, as well as dispensaries.

Additionally, Grow Solutions acquired Keys Organic and Hydroponic Supply (Keys) in Florida. This acquisition of Keys expands on Grow Solutions’ existing operations in the southeast by way of its Future Tech division through providing a strategic location for the entry of its One Love Garden Supply subsidiary into east coast markets.

Grow Solutions also acquired Mile High Hydro. This is a full service online grow store. It offers a wide-ranging line of gardening supply and agricultural products to growers across the country. Grow Solutions also acquired West Coast Organic and Hydroponic Supply (WCO) in Boring, Oregon.

Regarding Grow Solutions Holdings’ distribution division, it will allocate Company funds towards the manufacturing of proprietary products, bulk purchasing of an array of products and technologies, warehousing, and the distribution and wholesale of these products to Grow Solutions retailers serving the indoor high-yield agriculture industry.

The Company’s retail sales division uses Company funds for the acquisition of retail stores. These are stores that have shown substantial presence in strategic locations.

Grow Solutions Holdings, Inc. (GRSO), closed Wednesday's trading session at $0.01863, down 0.37%, on 25,000 volume with 4 trades. The average volume for the last 60 days is 310,159 and the stock's 52-week low/high is $0.0125/$0.15.

Bravada Gold Corp. (BGAVF)

Gold Investment Letter and Real Pennies reported earlier on Bravada Gold Corp. (BGAVF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Bravada Gold Corp. is a Nevada-focused exploration and development company. It has a large portfolio of high-quality properties. These properties encompass a range of development stages. This is from early-stage exploration to advanced-stage exploration and pre-development. Bravada Gold is based in Vancouver, British Columbia. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Bravada Gold retains residual working or royalty interests. The Company explores for precious metals in well-established gold trends in one of the globe’s best gold jurisdictions. At present, five of its Nevada properties are being funded by partners. In total this includes earn-in work expenditures of up to $6.5 million and payments to Bravada Gold of up to +$3.0 million in cash and shares. Bravada holds a royalty on eventual barite production on its Shoshone Pediment Project.

Regarding its Wind Mountain project, the Company’s plan is to drill-test for high-grade “Hishikari-type” gold/silver vein mineralization beneath the existing disseminated resource at Wind Mountain. Concerning the SF property, Bravada plans to drill-test for high-grade “Carlin-type” gold mineralization at this property.

Pertaining to the North Lone Mountain and South Lone Mountain projects, plans have not been finalized for Bravada Gold’s two claim groups. However, Nevada Zinc continues to expand the footprint of zinc mineralization on its claims towards Bravada’s South Lone Mountain claims. Should Nevada Zinc complete the purchase of these claims, Bravada will retain a royalty on base and precious metals.

This past December, Bravada Gold announced that drilling is underway at its 100 percent owned low-sulfidation Wind Mountain project. Two reverse-circulation holes are planned, one roughly 450m deep and the other roughly 750m deep. The design of the holes is to be proof-of-concept holes. More holes may be added depending on drilling costs and results. The Wind Mountain Project is the Company’s past-producing gold/silver property in north-western Nevada.

Last month, Bravada Gold reported that two proof-of-concept holes were completed in December and early January at the Wind Mountain Project. The reverse-circulation holes were drilled about 1,500m apart.

Alteration and geochemistry indicate that the southerly hole intersected mineralization with characteristics of being up-dip from a feeder zone. In addition, the northerly hole intersected characteristics of being down-dip from a feeder zone. This indicates that the feeder lies between these holes. Each hole intersected a low-angle fault, which separates the Tertiary volcanic and sedimentary host rocks from Mesozoic metamorphosed basement rocks.

Recently, Bravada Gold announced that it received notice that Coeur Explorations, Inc. elected to relinquish its option to purchase Bravada's interest in the Quito property positioned along the Austin Gold trend in central Nevada. Since July of 2015 Coeur Explorations has been funding Bravada Gold, as Operator, in the conduct of exploration at Quito, with recent focus upon completion of permitting to allow drilling this year at the Quito Extension target.

This target was developed during the 2016 exploration program. Around US$600,000 has been received by Bravada Gold by way of this funding, which has been credited to its earn-in obligations to earn its interest in Quito.

Mr. Joe Kizis, Bravada Gold President, said, "Exploration work funded by Coeur has greatly advanced Quito to a 'drill-ready' stage. Bravada will continue to permit four drill sites and plans to drill 4 to 6 holes for 1,600m beginning in the third quarter of 2018 with the intent to test the down-plunge extension of the high-grade mineralization that occurs along the intersection of two primary faults and several secondary faults; this target has not been tested to depth."

Bravada Gold Corp. (BGAVF), closed Wednesday's trading session at $0.085, even for the day. The average volume for the last 60 days is 19,475 and the stock's 52-week low/high is $0.0732/$0.2567.

Corix Bioscience, Inc. (CXBS)

InvestorsHub and OTC Markets reported previously on Corix Bioscience, Inc. (CXBS), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.

Corix Bioscience, Inc. is a next generation tissue cell culture to pharmaceutical grade cannabinoid oil (CBD) manufacturer. The Company is the developer of proprietary cannabis and industrial hemp strains using tissue cell cultures to propagate living plants. Corix has plans to patent the strains to be used in the pharmaceutical medical industries.

Cannabidiol (CBD) is one of at least 113 active cannabinoids identified in cannabis. Corix Bioscience is developing brand named products to be released early in 2018.

Corix Bioscience is based in Arizona. The Company’s laboratory and processing facility is in Carson City, Nevada. The fields for growing the plants are in Genoa, Nevada. Corix Bioscience’s location is on the Washoe Tribal Allotment in Minden, Nevada. The Company has secured a 25-year land lease with the Tribe family to cultivate and process the CBD and THCV oil.

The facility will be in the middle of a major corridor for product grown in Oregon, Northern California, and Nevada. Corix is already permitted to grow here. The Company has a number of other grows in a 25-mile radius and Southern Nevada.

The Company’s mission is to create clean and consistent products in medical grade facilities. It is now looking at expanding its mark into Washington, Oregon, California, and Arizona.

Corix Bioscience’s methods enable it to create and breed new and existing plant strains from tissue cells free of any pathogens or disease. The Company grows these plants to maturity and extracts the oils that are the "medicine" portion of the plant.

Corix Bioscience has purchased 100 percent of Pharmaceutical Development Corp. This enables Corix to commence selling its proprietary cannabis products internationally.

Pharmaceutical Development's manufacturing facility is in Lesotho, South Africa. It received the first cannabis license in all of South Africa.

Pharmaceutical Development has an export treaty. This treaty allows them to export cannabis and CBD oil to about 30-plus different countries in the European Union (EU), Canada, Australia, Mexico, Brazil and New Zealand.

Last month, Corix Bioscience announced that it will joint venture (JV) with ChampRX for its products. Corix will provide ChampRX with a 100 percent THC free product centered on athletes. Corix will be their official CBD manufacturer and a 25 percent equity holder in ChampRX.

In addition, Corix Bioscience will have access to the marketing for ChampRX and its partners. With this agreement, Corix will provide the science and manufacturing behind the products and ChampRX will market and promote the product. The World Anti-Doping Agency (WADA) recently decided to remove cannabidiol (CBD) from its list of banned substances in 2018.

Highlights from the past three months for Corix Bioscience include a rewarding harvest of industrial hemp in Carson City, Nevada; and purchasing $1mm worth of processing equipment fully in cash (without financing).

Highlights also include acquiring Pharmaceutical Development Corp LTD in Lesotho, South Africa; shipping its first set of samples to Switzerland and beginning marketing in the European market, as well as creating the aforementioned Joint Venture with ChampRX.

Corix Bioscience, Inc. (CXBS), closed Wednesday's trading session at $0.40, down 6.98%, on 34,550 volume with 8 trades. The average volume for the last 60 days is 27,750 and the stock's 52-week low/high is $0.31/$2.20.

nFüsz, Inc. (FUSZ)

InvestorsHub and MarketWatch reported on nFüsz, Inc. (FUSZ), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

nFüsz, Inc. (formerly bBooth) is a digital technology enterprise headquartered in Hollywood, California. Its proprietary next generation interactive video technology is the heart of its new broadcast and cloud-based, Software-as-a-Service (SaaS) products. The Company’s service is built around its proprietary 'Video-First' Notifi technology. This technology places interactive video front and center in all customer and prospect communications. nFüsz lists on the OTCQB.

The Company provides subscription-based Customer Relationship Management (CRM), sales lead generation, and social engagement software on mobile and desktop platforms. These are for sales-based organizations, consumer brands, and artists looking for greater levels of engagement and higher conversion rates. The Company’s software platform can accommodate any size campaign or sales organization. Also, it is enterprise-class scalable to meet the needs of today's worldwide organizations.

nFüsz has its notifiADS product. NotifiADS permits its customers to embed their interactive videos in online ads they can place almost anywhere online.

nFüsz products also include notifiWEB. This product enables customers to create and display sales, product, or corporate videos with ‘clickable’ interactive links in the actual video on their ‘WordPress’ and other template-based websites, viewable on desktop and mobile devices.

notifiCRM is nFüsz’s flagship product. notifiCRM is a cloud-based SaaS product. It is provided on a subscription basis, as a totally branded white labeled desktop, mobile, and web-based application (or embedded in customers’ existing applications through an API).

nFüsz built an enterprise-class, fully scalable platform around its core technology for the creation and delivery of interactive videos as the centerpiece of a CRM and Lead Generation solution for any sales-based organization.

In addition, the Company has its notifiLINKS product. With it, customers can take that same interactive video described in the abovementioned products, with all the interactive elements intact and distribute to them via Email; Text Messaging; Social Media; Electronic Invitations, and more.

nFusz has a new partnership with Alpha Networkers Quinn and Maree Moran, to promote nFusz’s notifiCRM, interactive video-based CRM product, to their worldwide sales network of more than 75,000 people.

notifiCRM creates engagement, employing interactive video with clickable calls-to-action in the video. Users can send concise, effective, corporate compliant and interactive videos via email, SMS messages, or distribute them on social media.

nFusz has entered into a strategic partnership with WFN1 News Corp. WFN1 News is the producer of iHeartRadio’s CEO Money - America’s Business Show, hosted by Mr. Michael Yorba, and heard on Talk Radio 1190 AM in Dallas/Fort Worth, Texas and online at www.wfn1.com.

This cross-promotional, advertising, and revenue share deal provides WFN1 and its clients with access to nFusz’s proprietary notifiCRM interactive video marketing technology, for enhanced promotion and sponsorship opportunities. nFusz in return will gain brand visibility and guaranteed business media coverage by way of ongoing radio spots and online ads.

Recently, nFusz announced the release of its “Entourage” package. This is a subscription-based account option for its notifiCRM service, which is the world’s first interactive video-based CRM, created specifically for the 100 million people involved with network marketing sales. A corresponding marketing campaign, titled “Network Marketing Made Easy,” launched on January 30, 2018, will promote the new package offering.

Furthermore, nFusz has engaged Concentrus, Inc. to speed upintegration of its notifiCRM interactive video technology into the cloud-based platforms of popular enterprise resource planning (ERP) and customer relationship management (CRM) providers.

nFüsz, Inc. (FUSZ), closed Wednesday's trading session at $0.455, down 3.21%, on 1,804,204 volume with 338 trades. The average volume for the last 60 days is 1,096,707 and the stock's 52-week low/high is $0.0531/$0.715.


The QualityStocks
Company Corner


Petroteq Energy Inc. (TSX.V:PQE) (OTCQX:PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF). Today, Petroteq Energy Inc. closed trading at $1.11099, up 0.66%, on 49,409 volume with 66 trades. The stock’s average daily volume over the past 60 days is 62,638, and its 52-week low/high is $0.015/$1.8892.

Blockchain technology has a wide range of applications across different industries, and Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF), a leading developer and provider of proprietary technology for the energy industry, has just demonstrated one more. The company’s innovative PetroBLOQ blockchain platform is a pioneer development in the oil and gas industry, aiming to take the shared economy concept one step further by making a number of industry intermediaries redundant and, consequently, reducing the cost of transactions in supply chain management (http://nnw.fm/6ZWyG).

Petroteq Energy Inc. (TSX.V: PQE) (OTCQB: PQEFF), with headquarters in Canada, seeks to create the world's largest pure-play cobalt exploration and development company. The company's current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.

The merger agreements with Cobalt One Ltd. and CobalTech Mining Inc., announced earlier this year, will result in a combined land position of more than 10,000 hectares (nearly 25,000 acres) in the Cobalt Camp containing approximately 50 past cobalt/silver producers and working mines. Initial test results from a mineralogical assessment of sample material taken from various historical mines located throughout the Cobalt Camp show both cobalt-rich and silver-rich mineralization styles. Samples taken at the former Bellellen mine, located within the Greater Cobalt Project in Ontario, show high grade cobalt assays, prompting First Cobalt to increase its drilling program at that site.

Petroteq Energy Inc. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world's current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

The company's clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, Petroteq Energy Inc. and its mining interests are primed for success.

Petroteq Energy Inc. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

Petroteq Energy Inc. Company Blog

Petroteq Energy Inc. News:

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) Introduces Blockchain Innovation to Reduce Oil & Gas Industry Transaction Costs

Petroteq Energy Launches Communication Strategy

Petroteq Energy Announces Completion of Facility Improvements Bringing Production Capacity to 1000 Barrels Per Day


The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $1.60, up 15.94%, on 779,435 volume with 803 trades. The stock’s average daily volume over the past 60 days is 777,744 and its 52-week low/high is $0.6171/$3.2929.

ABcann Global Corporation (TSXV:ABCN) is pleased to announce that it has closed its bought deal financing, as previously announced on January 29, 2018, of: (i) 11,500,000 units (each, a “Unit”) of the Company at a price of $3.50 per Unit, for aggregate gross proceeds of $40,250,000; and (ii) 30,000 6.0% unsecured convertible debentures (each, a “Convertible Debenture”) of the Company at a price of $1,000 per Convertible Debenture, for aggregate gross proceeds of $30,000,000.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

ABcann Global Completes $70 Million Bought Deal Financing and $4.8 Million Exercise of Underwriters’ Over-Allotment Option

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF) Sees IIROC Trade Halt and Restart on the TSX-V

ABcann Completes Acquisition of Harvest Medicine


The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO). Today, EVIO, Inc. closed trading at $1.43, up 12.60%, on 108,070 volume with 137 trades. The stock’s average daily volume over the past 60 days is 125,909, and its 52-week low/high is $0.47/$2.70.

To coincide with the opening of the adult recreational market, a plethora of rules and rubrics has been issued. California MMJ businesses will have until July 2018 to ensure compliance. As a result, demand for cannabis testing services in California is set to increase rapidly, a development that means EVIO, Inc. (OTCQB: EVIO), which has acquired testing facilities in Berkeley, California, is in the right place at the right time. Also today, the company announced that it is on track to double its number of cannabis testing laboratories in 2018, according to management.

EVIO, Inc. (EVIO), via the EVIO Labs division, is the nation's leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation's cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation's leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today's fastest growing industry. Disclaimer

EVIO, Inc. Company Blog

EVIO, Inc. News:

EVIO, Inc. (EVIO) Sets Up in California as July 2018 Mandatory Cannabis Testing Deadline Approaches

EVIO to Double Number of Cannabis Testing Labs from 9 to 18 in 2018

EVIO Inc. Update--Letter to Shareholders

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings Inc. (CHOOF). Today, Choom Holdings Inc. closed trading at $0.58, up 5.45%, on 96,988 volume with 61 trades. The stock’s average daily volume over the past 60 days is 50,181, and its 52-week low/high is $0.1099/$0.8612.

Choom (CSE: CHOO; OTCQB: CHOOF) today announced the appointment of Chris Gagan as Senior Vice President of Marketing to lead its brand strategy and execution.  Reporting to Chief Executive Officer, Chris Bogart, Mr. Gagan will provide overall leadership and guidance to the marketing function and all its specialities, as well as provide insight into the overall corporate strategy.

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s "Choom Gang," a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with "choom," the local's term for marijuana. Choom's trademark slogans pivot off another unconventional phrase ("Say Hello to…"), bringing a heady dose of good times and good friends together as the company invites investors to "Say Hello to Choom™" as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company's first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom's initial license applications to ensure the company's readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company's character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1's revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic "Aloha" vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company's growth strategy. Get ready to "Say Hello" to opportunity, good times and good friends with Choom™. Disclaimer

Choom Holdings Inc. Company Blog

Choom Holdings Inc. News:

Choom™ Appoints Chris Gagan as SVP Marketing

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) Evokes Good Times Vibe in Build up to Canadian Marijuana Legalization

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) is “One to Watch”

ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.66, up 0.46%, on 28,245 volume with 33 trades. The stock’s average daily volume over the past 60 days is 203,080 and its 52-week low/high is $0.40/$1.83.

Market analysis company ChineseInvestors.com (OTCQB: CIIX) this morning released details of the stock dividends related to the company’s anticipated spinoff of its hemp-related assets including its China-based wholly owned foreign enterprise, CBD Biotechnology Co. Ltd. and its wholly owned United States subsidiaries, ChineseHempOil.com, Inc. and Hemp Logic, Inc.

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News

CannabisNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Releases Stock Dividend Details Regarding Spinoff of Hemp-related Assets

ChineseInvestors.com, Inc. (CIIX) Recognizes Untapped CBD Market for Chinese-Speaking Individuals

ChineseInvestors.com, Inc. (CIIX) Pursuing a Diversified Future in Cryptocurrency, Baijiu and Cannabis

Skinvisible, Inc. (SKVI)

The QualityStocks Daily Newsletter would like to spotlight Skinvisible, Inc. (SKVI). Today, Skinvisible, Inc. closed trading at $0.0214, up 0.94%, on 70,000 volume with 11 trades. The stock’s average daily volume over the past 60 days is 216,183 and its 52-week low/high is $0.02/$0.33.

An outbreak of the deadly influenza A (H3N2) virus has devastated families across the United States this winter. Traditionally, the elderly and the very young are most vulnerable to the flu, but, this time around, it is attacking people of all ages. This outbreak follows on the heels of the potent H7N9 avian influenza virus, which has the potential to spread globally, although largely confined to China at present. Hand hygiene is vital to reduce the risk of contracting these flu strains. Skinvisible, Inc. (OTCQB: SKVI) has developed a unique hand sanitizer, DermSafe®, which offers long-term protection against harmful microbes.

Skinvisible, Inc. (SKVI) through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is a Research and Development company whose patented Invisicare® technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible's formulations to sell their own patented product and combat generic competitors.

A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of "gold standard" dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.

Invisicare® is a high performance topical and transdermal delivery system which enhances the delivery of drugs and other ingredients to and through the skin. The key to Skinvisible's patented technology and trademarked Invisicare® family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Invisicare® can be a key component of life cycle management, extending the life with a new patent-protected product, dramatically expanding the company's revenue stream.

Independent studies of Invisicare® have shown the following benefits:

  • Active ingredients stay on the skin for up to four hours or more and resist wash off and rub off.
  • Delivery method results in improved efficacy, reduced skin irritation and lower required dosage.
  • Unique formulations are non-drying and provide the ability to control the release of active ingredients.
  • Products form a protective barrier, which means normal skin respiration and perspiration occur and the product wears off as part of the skin's natural exfoliation process.

Terry Howlett, President, founder and CEO of Skinvisible Inc., said the Company has more than 15 years of scientific research and product development experience. All development is conducted using stringent pharmaceutical standards. The Company has licensed a number of its formulations including a prescription hemorrhoid cream in the USA, its anti-aging Kintari® line of products and DermSafe®, its non-alcohol hand sanitizer to a licensee in China. Producing licensed products for the booming cannabis industry is also an important element of the company's business strategy.

Skinvisible's foray into the rapidly expanding market for medicinal and recreational cannabis products is already underway with the development of the company's first hemp-derived CBD (cannabidiol) products. Skinvisible has negotiated an exclusive licensing deal in Canada with Canopy Growth Corporation, one of the world's leading cannabis companies. As part of the company's overall growth strategy, Skinvisible is also negotiating with a Licensed Producer in Las Vegas where Skinvisible scientists will develop THC (tetrahydrocannabinol) products for the legal recreational and medical marijuana market for the USA. Notably, Skinvisible is actively pursuing potential licensees through-out the world where medical cannabis is legal. These licensees will have the exclusive right to manufacture and distribute Skinvisible's cannabis products within their territory.

"We are excited about the results we are already seeing just with our hemp-derived CBD products," Howlett says. "Our science shows that our CBD products release almost four times that of market leaders and our transdermal product had an 81% penetration rate at 6 hours. These results are significant and provide the difference between ordinary cannabis products and ones enhanced by Invisicare."

The Company's business model includes out-licensing its formulations for a development fee, license fee and on-going royalties in addition to selling its Invisicare polymers to its licensees. Disclaimer

Skinvisible, Inc. Blog

Skinvisible, Inc. News:

Skinvisible, Inc.’s (SKVI) Topical Delivery Tech Provides Effective Protection against Deadly Flu Viruses

NetworkNewsBreaks – Skinvisible, Inc. (SKVI) Preparing to Enter the Post-Surgical Pain Management Market through Proposed Merger

Skinvisible, Inc. (SKVI) Aims to Increase Shareholder Value through Proposed Deal with Quoin

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $1.37, up 0.74%, on 171,446 volume with 343 trades. The stock’s average daily volume over the past 60 days is 488,100 and its 52-week low/high is $0.27/$2.54.

NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company for business, today announces the audio version of Lexaria Bioscience Corp.’s (CSE:LXX) (OTCQX:LXRP) recent press release: “Lexaria Bioscience Corp. Enters Global Licensing Agreement with Neutrisci International Inc. (TSX-V:NU) (OTCQB:NRXCF).” To hear the Lexaria Bioscience Corp. AudioPressRelease (APR) version, visit: http://nnw.fm/IgDv2. To read the original press release, visit: http://nnw.fm/4LfAe.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

NetworkNewsAudio Covers Global Licensing Agreement of Lexaria Bioscience Corp. (CSE:LXX) (OTCQX:LXRP) and NeutriSci International Inc. (TXS-V:NU) (OTCQB:NRXCF)

Lexaria Enters Licensing Agreement with Cannabis Edibles Infusion Company

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Global Licensing Agreement with Neutrisci International Inc. (TSX-V: NU) (OTCQB: NRXCF)

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.4645, off by 4.52%, on 10,817,564 volume with 1,953 trades. The stock’s average daily volume over the past 60 days is 13,681,842, and its 52-week low/high is $0.0006/$0.957.

Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on PotNetwork Holdings, Inc. (OTC PINK: POTN), a holding company for its subsidiaries, PotNetwork, Inc., and First Capital Venture Co., the owner of Diamond CBD, Inc., the maker of Diamond CBD oils.

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

PotNetwork Reaches New Sales Milestones and Concentrates its Focus, Analysts Review and Target

PotNetwork Holding Inc. Exceeds 1 Million in Sales for First 15 Days of February

PotNetwork Holding’s Diamond CBD Books Over $270,000 in Sales at CHAMPS Winter Show at Las Vegas Convention Center

Veritas Pharma, Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP)

The QualityStocks Daily Newsletter would like to spotlight Veritas Pharma, Inc. (VRTHF). Today, Veritas Pharma, Inc. closed trading at $0.4776, off by 4.48%, on 30,809 volume with 18 trades. The stock’s average daily volume over the past 60 days is 213,852 and its 52-week low/high is $0.22/$0.881.

Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP) (“Veritas” or the “Company”) is pleased to announce that it has entered into a Memorandum of Understanding (“MoU”) with BioCan Technologies Inc. (“BioCan”) of Calgary, Alberta to collaborate with BioCan on an exclusive basis to undertake further investigations of cannabis strains being developed by its research arm, Cannevert Therapeutics Ltd. (“CTL”).

Veritas Pharma, Inc. (CSE: VRT) (OTCQB: VRTHF) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas' R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma's goal is to perform clinical trials to prove the efficacy of the designated lead cannabis strains and to market the clinically effective cultivars as prescription medicines in a fast-track protocol.

Veritas Pharma's management and R&D team comprises decades of pharmaceutical, clinical and scientific research expertise into several key industry leaders. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry, leads the company as its CEO. In addition to a team of trained technicians and students working out of academic facilities, Veritas Pharma is pleased to have a renowned group of scientists on board to lead its research efforts. Team members hold 10 PhDs/MD licenses with expertise in chemistry, pharmacology and clinical trials.

Veritas Pharma's mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company's approach, combined with its strategic alliances, will effectively address the medical community's concerns over the complexities of cannabis potency, efficacy, quality and content in the nearly 800 marijuana strains currently known in the world. Opportunities for innovation and scientific advancement related to the field of cannabis therapeutics will accelerate the knowledge base and provide a valuable alternative to the global opioid market that is estimated at nearly U.S. $35 billion. A growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as those provided by cannabis.

Veritas Pharma's clinical cannabis development pipeline includes R&D for chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder. The strategic alliance formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants, which they plan to patent protect for a variety of unmet medical needs, are destined to help patients suffering with chronic and debilitating symptoms of a variety of medical issues. Over 250 experiments have been performed so far with another 150 pharmacological and biological studies conducted. Veritas Pharma has also entered into an agreement with Sechelt Organic Marijuana Inc., which has a Licensed Producer application pending with Health Canada, to acquire 100 percent ownership in the company.

Results of the company's research to date illustrate Veritas' unique place in the medical marijuana industry. The company's focus on the biological effect of the actual spectrum of cannabinoids sets Veritas apart as it seeks to patent and protect results-driven strains. Disclaimer

Veritas Pharma, Inc. Blog

Veritas Pharma, Inc. News:

Veritas Pharma Signs Memorandum of Understanding with BioCan Technologies

Veritas Pharma Completes Share Purchase Agreement of Sechelt Organic Marijuana Corp.

Veritas Pharma Provides Corporate Update on Q1 2018

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0195, off by 2.50%, on 5,388,156 volume with 188 trades. The stock’s average daily volume over the past 60 days is 15,763,320, and its 52-week low/high is $0.0141/$0.16.

Payment solutions company Global Payout, Inc. (OTC: GOHE), through its SecurCapital Corp. subsidiary, today announced the launch of its integrated philanthropic company, SecurFoundation. To view the full press release, visit: http://cnw.fm/S9Bwa

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

CannabisNewsBreaks – Global Payout, Inc. (GOHE) Subsidiary Announces Launch of Integrated Philanthropic Company

CannabisNewsBreaks – Global Payout, Inc. (GOHE) Subsidiary CEO Comments on Crypto Cowboy, Sun Pacific Holding Corp. (SNPW) Agreement

CannabisNewsAudio Announces Audio Press Release (APR) on Global Payout, Inc. Grasping Opportunity in Cannabis Industry's Interwoven Verticals


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(VTNL) +273.75%


(ECYT) +41.19%


Daily Trade Alert
(AAXN) +27.82%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251